What one share of Ocular Therapeutix holds
We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology.
Ocular Therapeutix’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.24 |
|---|---|
| Profit | −$1.41 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$1.19 |
| Cash and investments | $2.73 |
| Debt | $0.33 |
| Book value | $2.37 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $0.00 | −$5.60 | $0.08 | −$5.07 | — | −$18.48 |
| 2013 | — | −$5.11 | $0.15 | −$5.00 | — | −$22.22 |
| 2014 | $0.07 | −$2.69 | $0.12 | −$2.04 | — | — |
| 2015 | $0.08 | −$1.71 | $0.08 | −$1.53 | — | $3.62 |
| 2016 | $0.08 | −$1.80 | $0.08 | −$1.45 | — | $2.08 |
| 2017 | $0.07 | −$2.20 | $0.29 | −$2.04 | — | $0.88 |
| 2018 | $0.05 | −$1.57 | $0.05 | −$1.34 | — | $0.86 |
| 2019 | $0.09 | −$1.91 | $0.05 | −$1.76 | — | −$0.07 |
| 2020 | $0.29 | −$2.56 | $0.01 | −$0.90 | — | $1.00 |
| 2021 | $0.53 | −$0.98 | $0.01 | −$0.81 | — | $1.15 |
| 2022 | $0.62 | −$0.97 | $0.04 | −$0.77 | — | $0.46 |
| 2023 | $0.68 | −$1.02 | $0.07 | −$0.89 | — | $0.79 |
| 2024 | $0.40 | −$1.22 | $0.01 | −$0.86 | — | $2.00 |
| 2025 | $0.28 | −$1.42 | $0.06 | −$1.16 | — | $3.03 |
Common questions about Ocular Therapeutix
How much does one share of Ocular Therapeutix earn?
Over the last 12 months, Ocular Therapeutix lost $1.41 for each share on $0.24 of sales.
Does Ocular Therapeutix pay a dividend?
Ocular Therapeutix didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Ocular Therapeutix’s book value per share?
Ocular Therapeutix’s book value is $2.37 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Ocular Therapeutix have?
Each share of Ocular Therapeutix has $2.73 of cash and investments and $0.33 of debt, as of June 30, 2026.
What is Ocular Therapeutix’s free cash flow per share?
−$1.19 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Ocular Therapeutix bought back shares?
Ocular Therapeutix’s share count rose about 7323% from 2012 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.